Analysts Offer Predictions for Aquinox Pharmaceuticals, Inc.’s Q1 2018 Earnings (AQXP)

Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) – Research analysts at Leerink Swann issued their Q1 2018 EPS estimates for Aquinox Pharmaceuticals in a research report issued on Wednesday. Leerink Swann analyst P. Matteis expects that the company will earn ($0.68) per share for the quarter. Leerink Swann also issued estimates for Aquinox Pharmaceuticals’ Q2 2018 earnings at ($0.71) EPS, Q3 2018 earnings at ($0.59) EPS and Q4 2018 earnings at ($0.55) EPS.

AQXP has been the topic of several other research reports. Zacks Investment Research lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 10th. ValuEngine lowered Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 15th. Needham & Company LLC restated a “buy” rating and set a $25.00 price target on shares of Aquinox Pharmaceuticals in a report on Thursday. BidaskClub upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. Finally, Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, August 8th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. Aquinox Pharmaceuticals has an average rating of “Hold” and an average target price of $22.50.

TRADEMARK VIOLATION NOTICE: This story was reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another site, it was illegally stolen and reposted in violation of US & international copyright and trademark legislation. The original version of this story can be read at https://www.chaffeybreeze.com/2017/11/12/analysts-offer-predictions-for-aquinox-pharmaceuticals-inc-s-q1-2018-earnings-aqxp.html.

Shares of Aquinox Pharmaceuticals (NASDAQ AQXP) opened at $10.88 on Friday. Aquinox Pharmaceuticals has a twelve month low of $10.68 and a twelve month high of $19.97.

A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Aquinox Pharmaceuticals by 6.6% in the 2nd quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock valued at $3,974,000 after acquiring an additional 17,455 shares during the last quarter. Geode Capital Management LLC grew its position in Aquinox Pharmaceuticals by 10.0% in the 1st quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock valued at $2,028,000 after acquiring an additional 11,035 shares during the last quarter. Nexthera Capital LP bought a new position in Aquinox Pharmaceuticals in the 2nd quarter valued at $1,276,000. Northern Trust Corp grew its position in Aquinox Pharmaceuticals by 3.3% in the 2nd quarter. Northern Trust Corp now owns 83,207 shares of the company’s stock valued at $1,171,000 after acquiring an additional 2,691 shares during the last quarter. Finally, Sphera Funds Management LTD. grew its position in Aquinox Pharmaceuticals by 21.7% in the 3rd quarter. Sphera Funds Management LTD. now owns 75,535 shares of the company’s stock valued at $1,072,000 after acquiring an additional 13,450 shares during the last quarter. 95.15% of the stock is currently owned by institutional investors.

About Aquinox Pharmaceuticals

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Earnings History and Estimates for Aquinox Pharmaceuticals (NASDAQ:AQXP)

Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply